Subscribe Become an Author Log In

BiopharmaTrend.com

Covering emerging technologies, innovations, and companies

Biopharma news


Learning From Nature: New Antibiotics Found In Our Body

   by Andrii Buvailo    2467
Learning From Nature: New Antibiotics Found In Our Body

To date, nature has been the best teacher for drug discovery scientists, especially for those who develop antimicrobial drugs. Lately, a new example proving this notion emerged in press - a recent publication in a prestigious research journal Nature describing a new powerful method of identifying yet unknown classes of antibiotics by learning from bacteria living in our body - microbiota.

A Second Chance for Integrins: Biotech Startup Morphic Therapeutic Reinvents Old Target

   by Andrii Buvailo    1804
A Second Chance for Integrins: Biotech Startup Morphic Therapeutic Reinvents Old Target

Integrins are a group of transmembrane receptors playing a major role in cell-cell and cell-extracellular matrix (ECM) interactions. When triggered, integrin receptors transduce signals to the interior of the cell, providing quick and flexible “status update” about chemical composition and mechanical status of the ECM. It results in a cellular response, such as a change in the cell shape, regulation of the cell cycle, adjusting motility, or adding new receptors to the cell membrane.

Facebook and Napster founder Sean Parker is going to “hack cancer” by CRISPR technology

   by Andrii Buvailo    1814
Facebook and Napster founder Sean Parker is going to “hack cancer” by CRISPR technology

A billionaire Sean Parker, known as a founder of Facebook and Napster, has steeply entered Life Sciences industry to fund the world’s first-ever CRISPR/Cas9 trial, backed by US federal authorities. Upon success, the probability of which is now hard to assess, this technology can revolutionize the way cancer and many other diseases are treated. This time, Sean Parker is playing a bigger game than ever, however, uncertainty is huge.